Medidata's Experience-based AI Earns Top Luminary Rating in Everest Group 2026 Review
MWN-AI** Summary
Medidata, a key player in clinical trial solutions and a brand of Dassault Systèmes, has achieved the prestigious “Luminary” rating in Everest Group’s 2026 Innovation Watch for AI Applications in Clinical Development. This recognition stems from Medidata’s pioneering experience-based AI capabilities, which were instrumental in supporting a significant 80% of FDA novel drug approvals in 2025. Among 18 global providers evaluated, Medidata stood out as the sole company to achieve a perfect score for market adoption, underscoring the value of its active AI solutions.
The Everest Group report highlights the transformative impact of AI in clinical development, focusing on innovations like Generative AI for data synthesis, Agentic AI for workflow automation, and Advanced AI for trial simulation. Medidata’s rank as a Luminary reflects its ability to transition AI applications from theoretical models to measurable outcomes in real-world settings.
Key efficiencies driven by Medidata's AI solutions include a 37% reduction in patient enrollment times, an 80% decrease in data review cycles, and savings of 70 hours in medical coding for every 1,000 terms. Nisarg Shah, practice director at Everest Group, emphasized Medidata's comprehensive suite of AI capabilities and extensive proprietary data assets, which enhance its competitive edge in the clinical landscape.
Tom Doyle, CTO of Medidata, remarked on the significance of receiving this recognition, illustrating the immediate benefits their AI provides to critical drug development efforts. With over 25 years of innovation and a robust user base exceeding 1 million, Medidata continues to enhance its end-to-end platform, delivering therapies to patients with unprecedented speed. The company’s commitment to harnessing advanced AI technologies positions it as a leader in clinical trials and drug development.
MWN-AI** Analysis
Medidata’s recent achievement of being awarded the highest "Luminary" rating by Everest Group for its innovative application of experience-based AI in clinical trials presents a unique investment opportunity in the life sciences technology sector. As the only company to earn a 100% score for market adoption, Medidata has demonstrated not only technological leadership but also substantial tangible value in a sector increasingly reliant on efficient drug development processes.
Investors should view this accolade as a crucial indicator of Medidata’s competitive edge. The company claims to support a staggering 80% of FDA novel drug approvals, demonstrating a deep integration of AI technologies that significantly enhance the clinical trial lifecycle—reducing enrollment times by 37% and shortening data review cycles by up to 80%. Such metrics translate to accelerated time-to-market for therapeutic interventions, making Medidata a preferred partner in an industry where speed can equate to survival.
The integration of advanced AI techniques—Generative, Agentic, and Advanced AI—positions Medidata not only as a service provider but as a pivotal player in transforming clinical development challenges into opportunities for efficiency and lower costs. The proprietary data assets Medidata possesses further bolster its value, acting as a powerful differentiator among its competitors.
With Dassault Systèmes backing Medidata, investors can be confident in the financial strength and technological capabilities that underpin this brand. As the industry leans towards innovative digital solutions, Medidata is well-poised for growth and continued relevance.
In conclusion, given Medidata’s proven track record and recent recognitions, it appears to be an attractive investment for those looking to capitalize on the intersection of AI and healthcare, particularly as the demand for accelerated drug development processes continues to rise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has secured the highest “Luminary” rating in Everest Group’s 2026 Innovation Watch: AI Applications in Clinical Development. The ranking highlights the industry-leading impact of Medidata’s experience-based AI functionality, which now supports 80% of FDA novel drug approvals in 2025. Rated highest among 18 global providers, Medidata was the only company to receive a 100% score for market adoption, reflecting the tangible value of its launched and active AI solutions.
According to Everest Group®, the report evaluates AI applications actively modernizing the landscape, including Generative AI for data synthesis, Agentic AI for autonomous workflow streamlining, and Advanced AI for digital twins and trial simulations. Medidata’s recognition as a Luminary is rooted in its ability to transition AI from theory to measurable performance.
The Value of Launched AI
Medidata is embedding experience-based AI across the end-to-end Medidata Platform, delivering significant efficiencies to the clinical trial lifecycle, including:
- Up to 37% reduction in enrollment times: Improved identification of sites with historically high enrollment for similar indications.
- Up to 80% shorter data review cycles: Allowing sponsors to reach database lock and analysis significantly faster.
- 70 hours saved for every 1,000 terms coded: Delivering massive operational scale through automated medical coding.
“With a comprehensive suite of AI capabilities ranging from data analytics to digital imaging, and its ‘AI for Impact’ approach, Medidata is embedding AI across its entire clinical trial platform,” said Nisarg Shah, practice director at Everest Group. “Medidata’s strong proprietary data assets further strengthen its differentiation. By applying Generative, Agentic, and Advanced AI to address the pressing challenges in clinical development, Medidata helps clients realize tangible and increasing returns from their AI investments.”
“This recognition from Everest Group validates the immediate value our AI functionality is delivering for the world's most critical drug programs,” said Tom Doyle, chief technology officer, Medidata. “Our 100% market adoption score and our support of 80% of 2025 FDA novel drug approvals proves that the industry is turning to Medidata for proven, experience-based AI. We are focused on putting these advanced tools into the hands of our customers today to deliver therapies to patients with unprecedented speed.”
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating over 25 years of ground-breaking technological innovation across more than 38,000 trials and 12 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com.
Contact:
For interviews and questions, please contact Medidata PR
Analyst Relations
FAQ**
How does Medidata's Luminary rating from Everest Group impact Dassault Systèmes S.A. DASTF’s overall strategy in the life sciences sector, particularly in AI-driven clinical trial solutions?
What specific AI applications developed by Medidata under Dassault Systèmes S.A. DASTF are contributing to the 80% of FDA novel drug approvals supported in 2025?
In what ways does Medidata’s 100% market adoption score reflect the competitive advantages of Dassault Systèmes S.A. DASTF in the clinical development landscape?
Can Medidata’s experience-based AI functionality provide insights into further innovations that Dassault Systèmes S.A. DASTF might pursue in other industries beyond life sciences?
**MWN-AI FAQ is based on asking OpenAI questions about Dassault Systemes S.A. (OTC: DASTF).
NASDAQ: DASTF
DASTF Trading
0.43% G/L:
$21.09 Last:
1,750 Volume:
$20.50 Open:
